Vertex Pharmaceuticals (VRTX) Return on Capital Employed (2010 - 2026)

Vertex Pharmaceuticals' Return on Capital Employed history runs 17 years deep, the most recent figure standing at 21.1% for Q1 2026.

• In Q1 2026, Return on Capital Employed rose 2503.0% year-over-year to 21.1%; the TTM figure through Mar 2026 stood at 21.1% (up 2503.0% YoY), while the FY2025 annual figure was 20.63%, up 2185.0% from the prior year.
• Return on Capital Employed was 21.1% for Q1 2026 at Vertex Pharmaceuticals, up from 19.51% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 33.0% in Q2 2022 to a low of 3.92% in Q1 2025.
• Historically, Return on Capital Employed has averaged 17.94% across 5 years, with a median of 21.1% in 2026.
• The sharpest annual moves came in 2024 and 2026: Return on Capital Employed sank 2620 bps in 2024, then jumped 2503 bps in 2026.
• A 5-year view of Return on Capital Employed shows it stood at 29.33% in 2022, then plunged by 30 bps to 20.51% in 2023, then tumbled by 106 bps to 1.24% in 2024, then jumped by 1677 bps to 19.51% in 2025, then rose by 8 bps to 21.1% in 2026.
• The last three Return on Capital Employed figures came in at 21.1% (Q1 2026), 19.51% (Q4 2025), and 19.99% (Q3 2025), per Business Quant data.